Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- JGC Takes Over CROBusiness from Tokyo CRO
October 11, 2010
- EML4-ALK Mutations Seen in 5.2% of Japanese Lung Cancer Patients
October 11, 2010
- Nippon Kayaku's NK105 Found Effective for Stomach Cancer in PII
October 11, 2010
- Takeda to Construct New Formulation Plant in Hikari
October 4, 2010
- Banyu Warned about Payment to Doctors Attending Januvia Seminars
October 4, 2010
- Canagliflozin Significantly Reduces HbA1c, Weight in PIIb
October 4, 2010
- Takeda Launches Dexilant in Canada
October 4, 2010
- EMA Recommends Suspension, US FDA Restricts Access to Avandia
October 4, 2010
- Diabetes Increasing in Asia: EASD President Prof. Smith
October 4, 2010
- MTPC Transfers 3 Long-Listed Products to Its Subsidiary
October 4, 2010
- Ono Applies for the Antiemetic Fosaprepitant
October 4, 2010
- EASD Welcomes GL Proposed by EMA
October 4, 2010
- BMS to Acquire ZymoGenetics through Tender Offer
October 4, 2010
- Dabigatran Receives Recommendation by FDA Committee: BI
October 4, 2010
- Otsuka to Codevelop OPA-6566 for Glaucoma with Acucela
October 4, 2010
- Daiichi Sankyo Completes Tender Offer for Zenotech Lab
October 4, 2010
- FDA Accepts NDA for Aricept Transdermal Patch: Eisai, Teikoku Seiyaku
October 4, 2010
- Takara Bio to Obtain Anticancer Agent from M's Science
October 4, 2010
- Japan's Own COI Disclosure System Necessary: Mr Hirai
October 4, 2010
- FDA Advisory Committee Not Recommend Approval for Lorcaserin: Eisai
October 4, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…